Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check9 days agoChange DetectedThe study record for a Phase 2 trial of pembrolizumab alone or with acalabrutinib in advanced non-small cell lung cancer is displayed, including its completed status, eligibility criteria, treatment arms, and outcome measures.SummaryDifference41%

- Check16 days agoChange DetectedThe site revision label was updated from v3.7.2 to v3.8.0 on the page displaying a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide notice announces the NIH website transition and says federal agencies are adopting “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision changed from v3.7.1 to v3.7.2; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site revision label in the page footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study record content and navigation, which indicates the study page is currently inaccessible.SummaryDifference17%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.